HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116 clinical trials

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome.

This study is testing a new medicine, HZN-1116, for Sjögren's Syndrome. It wants to see if the medicine can make people feel better and improve their symptoms, while also checking if it's safe to use. Some people will get the real medicine, and others a dummy treatment.